Leprosy (Hansen’s Disease)

Leprosy patient

Leprosy patient, Arran Reeve (Traité pratique et théorique de la lèpre, 1886)

Leprosy, or Hansen’s disease, is an infectious disease caused by the bacillus, Mycobacterium leprae. The disease is slow-growing and minimally contagious (despite its historical reputation). Leprosy primarily affects the skin, peripheral nerves, mucosa and delicate membranes, particularly around the eyes, nose, and upper respiratory tract. As with any disease that causes nerve damage, its greatest danger is the risk of secondary infections due to untreated and unnoticed injuries. But leprosy is entirely curable as a result of a multi-drug (MDT) regime consisting of dapsone, Clofazimine, and rifampicin.

For more information on leprosy (Hansen’s disease) consult:

World Health Organization (WHO): you can also locate the 2016-2020 Global Leprosy Strategy here.

Centers for Disease Control and Prevention

Despite the disease being easily curable, leprosy unfortunately persists throughout the world. It has since warranted the designation as a Neglected Tropical Disease (NTD), which is essentially a euphemism for a disease that largely affects the poor in poor countries (and is therefore ignored by much of the world). Still, a small number of organizations have committed themselves to fully eradicating leprosy:

The Novartis Foundation: while a part of Novartis International, the Swiss multinational pharmaceutical company, this foundation arguably exhibits some of the best funded and most innovative approaches to eradicating Hansen’s disease. The group was spotlighted in a NPR article this past year.

American Leprosy Missions: a continuation of the faith-based-organizations which were especially popular during the nineteenth and early-twentieth centuries.

Leprosy Research Initiative: essentially an umbrella-organization representing the International Federation of Anti-Leprosy Associations (ILEP).

The Leprosy Research Initiative has highlighted five research priorities that are universally recognized: 1) Early Detection; 2) Nerve Function Impairment and Reactions; 3) Inclusion; 4) Prevention of Disability; 5) Interrupt Transmission. The “inclusion” initiative is especially important as leprosy continues to carry an immense stigma.

Hansen Stamp

Commemorative stamp of Dr. Hansen

In fact, this is largely the reason why some scholars and researchers insist on the terminology of “Hansen’s disease” instead of “leprosy.” (Gerhard Armauer Hansen was the Norwegian physician who first identified Mycobacterium leprae) The label of “leper” is universally rejected and recognized as a derogatory, dehumanizing, and outdated source of stigma and discrimination. Organizations such as IDEA (International Association for Integration Dignity and Economic Advancement) have made it their mission to reverse such discrimination and stigma.

Finally, those interested in the history of leprosy in the United States should consult the National Hansen’s Disease Program, which also includes information about ongoing research and grant opportunities.

The International Leprosy Association has begun an exciting, multimedia history of those who have been affected by this disease.

Lepra is a UK-based international charity that continues to publish Leprosy Review, the only peer-reviewed, English language journal on leprosy–which can be read online for FREE.

 

Featured image: Father Damien on his funeral bier flanked by Mother Marianne Cope (courtesy of Wikimedia Commons)